Ann: Annual Report, page-33

I'm keeping my expectations very low with the hope of being pleasantly surprised. I don't know how many people got to the end of the annual report and read this part:

"As for the subsidiary in Israel, the departments that operates is finance and partly research and development, the other departments are in leave of absence. The active subsidiary in China - G Medical Innovations Asia Ltd, is currently working remotely. The Company’s active subsidiary in USA - G Medical Innovations USA Inc, part of the departments working remotely. As the event is still an ongoing event, the Company cannot estimate the potential effect on its short and mid-term activities and financial results."

How much can they realistically achieve with a lot of the workforce working remotely? I'm actually expecting revenue to be down this quarter (I don't believe that the IDTF business if growing). The Prizma has never sold despite being available for years - will FDA over the counter approval suddenly change that? The wording around the FCL MOU was very neutral after the Taiwan approval. The company says that they will also be pursuing other opportunities. That sounds like code for 'FCL is not going to amount to anything'. Italy is the litmus test for me. It's a real opportunity to see if the company can execute.

As always, I hope that my bearish sentiments are wrong and that the moon-shot scenarios being bandied about come true.